MIRA Pharmaceuticals, Inc. Increase (Decrease) in Accrued Interest Receivable, Net
MIRA Pharmaceuticals, Inc. (MIRA) reported Increase (Decrease) in Accrued Interest Receivable, Net of $161.50 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet · last filed 2026-05-14
- MIRA Pharmaceuticals, Inc. increase (decrease) in accrued interest receivable, net for the quarter ending 2026-03-31 was $161.50K.
- MIRA Pharmaceuticals, Inc. increase (decrease) in accrued interest receivable, net for fiscal 2024 was $14.47K.
| Period end | Increase (Decrease) in Accrued Interest Receivable, Net 3 month | Increase (Decrease) in Accrued Interest Receivable, Net 12 month |
|---|---|---|
| 2026-03-31 | $161.50K 10-Q · filed 2026-05-14 | |
| 2024-12-31 | $14.47K 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |